Press releases

We are excited to announce the launch of volume variants of Colli-Pee ® , our innovative urine-capturing device...

Novosanis announces deal with Fujirebio, a global leader in the field of in vitro diagnostics (IVD). Using our Colli-...

Wijnegem, Belgium, January 8, 2019: Novosanis, a privately-held, Belgian company founded as a spinoff company from the...

Novosanis announced today that the European Patent Office (EPO) has granted the company's patent application in Europe...

Wijnegem, Belgium, November 8, 2018: Novosanis, an innovative developer and producer of medical devices, announced...

Wijnegem, Belgium, July 26 2018: Novosanis announced today that Colli-Pee a non-invasive self-sampling device suited...

Novosanis, an innovative developer and producer of medical devices, announced today that Colli-Pee, a self-sampling...

Novosanis and Voxdale have been awarded the prestigious Henry Van de Velde Award in Design for Healthcare.

Interreg CrossCare grant allows Novosanis to build a next-generation Colli-Pee™ device

Novosanis develops UrNCollect TM for SelectMDx for Prostate Cancer IVD kit of MDxHealth

Novosanis, a medical device company based in Wijnegem Belgium, together with GeneFirst, a molecular diagnostic company...

Novosanis considers Japan as an important market due to its innovative vision towards healthcare and diagnostics.